Loading...

UCB

WBAG:UCB
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UCB
WBAG
€13B
Market Cap
  1. Home
  2. AT
  3. Pharmaceuticals & Biotech
Company description

UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The last earnings update was 84 days ago. More info.


Add to Portfolio Compare Print
UCB Share Price and Events
7 Day Returns
-0.4%
WBAG:UCB
2.1%
Europe Pharmaceuticals
-0.8%
AT Market
1 Year Returns
5.5%
WBAG:UCB
3.7%
Europe Pharmaceuticals
-9.6%
AT Market
UCB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
UCB (UCB) -0.4% -3.4% -11.6% 5.5% - -
Europe Pharmaceuticals 2.1% 1.9% -3.4% 3.7% 2.8% 6.3%
AT Market -0.8% -6.6% 0.2% -9.6% 36.8% 21.7%
1 Year Return vs Industry and Market
  • UCB outperformed the Pharmaceuticals industry which returned 3.7% over the past year.
  • UCB outperformed the Market in Austria which returned -9.6% over the past year.
Price Volatility
UCB
Industry
5yr Volatility vs Market

Value

 Is UCB undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of UCB to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for UCB.

WBAG:UCB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 13 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year AT Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WBAG:UCB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AT Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.8%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.695 (1 + (1- 29%) (11.51%))
0.834
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.51% + (0.834 * 6.8%)
6.18%

Discounted Cash Flow Calculation for WBAG:UCB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for UCB is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WBAG:UCB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.18%)
2019 880.35 Analyst x6 829.10
2020 1,030.38 Analyst x6 913.91
2021 1,111.93 Analyst x4 928.82
2022 1,117.00 Analyst x1 878.74
2023 945.00 Analyst x1 700.15
2024 930.63 Est @ -1.52% 649.36
2025 922.15 Est @ -0.91% 605.99
2026 917.68 Est @ -0.48% 567.94
2027 915.97 Est @ -0.19% 533.88
2028 916.18 Est @ 0.02% 502.92
Present value of next 10 years cash flows €7,110.80
WBAG:UCB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €916.18 × (1 + 0.51%) ÷ (6.18% – 0.51%)
€16,236.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €16,236.72 ÷ (1 + 6.18%)10
€8,912.78
WBAG:UCB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €7,110.80 + €8,912.78
€16,023.58
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €16,023.58 / 188.91
€84.82
WBAG:UCB Discount to Share Price
Calculation Result
Value per share (EUR) From above. €84.92
Current discount Discount to share price of €69.04
= -1 x (€69.04 - €84.92) / €84.92
18.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price UCB is available for.
Intrinsic value
19%
Share price is €69.04 vs Future cash flow value of €84.92
Current Discount Checks
For UCB to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • UCB's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • UCB's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for UCB's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are UCB's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WBAG:UCB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €4.20
ENXTBR:UCB Share Price ** ENXTBR (2019-05-23) in EUR €68.96
Europe Pharmaceuticals Industry PE Ratio Median Figure of 43 Publicly-Listed Pharmaceuticals Companies 21.99x
Austria Market PE Ratio Median Figure of 54 Publicly-Listed Companies 14.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of UCB.

WBAG:UCB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:UCB Share Price ÷ EPS (both in EUR)

= 68.96 ÷ 4.20

16.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UCB is good value based on earnings compared to the Europe Pharmaceuticals industry average.
  • UCB is overvalued based on earnings compared to the Austria market.
Price based on expected Growth
Does UCB's expected growth come at a high price?
Raw Data
WBAG:UCB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
4.7%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.85x
Austria Market PEG Ratio Median Figure of 32 Publicly-Listed Companies 1.12x

*Line of best fit is calculated by linear regression .

WBAG:UCB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.41x ÷ 4.7%

3.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UCB is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on UCB's assets?
Raw Data
WBAG:UCB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €33.40
ENXTBR:UCB Share Price * ENXTBR (2019-05-23) in EUR €68.96
Europe Pharmaceuticals Industry PB Ratio Median Figure of 94 Publicly-Listed Pharmaceuticals Companies 2.99x
Austria Market PB Ratio Median Figure of 61 Publicly-Listed Companies 1.22x
WBAG:UCB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:UCB Share Price ÷ Book Value per Share (both in EUR)

= 68.96 ÷ 33.40

2.06x

* Primary Listing of UCB.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UCB is good value based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess UCB's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. UCB has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is UCB expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is UCB expected to grow at an attractive rate?
  • UCB's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • UCB's earnings growth is positive but not above the Austria market average.
  • UCB's revenue growth is positive but not above the Austria market average.
Annual Growth Rates Comparison
Raw Data
WBAG:UCB Future Growth Rates Data Sources
Data Point Source Value (per year)
WBAG:UCB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 4.7%
WBAG:UCB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 1.2%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Austria Market Earnings Growth Rate Market Cap Weighted Average 9%
Austria Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WBAG:UCB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WBAG:UCB Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 4,667 1,217 949 5
2022-12-31 4,934 1,337 926 5
2021-12-31 5,099 1,288 942 8
2020-12-31 4,933 1,162 834 13
2019-12-31 4,721 1,044 761 13
WBAG:UCB Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 4,632 1,089 792
2018-06-30 4,569 1,092 872
2018-03-31 4,522 1,010 812
2017-12-31 4,474 927 752
2017-09-30 4,400 708
2017-06-30 4,325 780 664
2017-03-31 4,236 604 604
2016-12-31 4,147 427 543
2016-09-30 4,051 439
2016-06-30 3,955 66 334
2016-03-31 3,916 156 299

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • UCB's earnings are expected to grow by 4.7% yearly, however this is not considered high growth (20% yearly).
  • UCB's revenue is expected to grow by 1.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WBAG:UCB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from UCB Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WBAG:UCB Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.04 5.42 4.57 3.00
2022-12-31 4.91 5.05 4.82 3.00
2021-12-31 5.12 5.70 4.79 6.00
2020-12-31 4.50 4.91 4.16 7.00
2019-12-31 4.07 4.30 3.92 8.00
WBAG:UCB Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 4.20
2018-06-30 4.63
2018-03-31 4.31
2017-12-31 3.99
2017-09-30 3.76
2017-06-30 3.53
2017-03-31 3.20
2016-12-31 2.88
2016-09-30 2.32
2016-06-30 1.78
2016-03-31 1.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • UCB is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess UCB's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
UCB has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has UCB performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare UCB's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • UCB has delivered over 20% year on year earnings growth in the past 5 years.
  • UCB's 1-year earnings growth is less than its 5-year average (5.3% vs 43%)
  • UCB's earnings growth has not exceeded the Europe Pharmaceuticals industry average in the past year (5.3% vs 12%).
Earnings and Revenue History
UCB's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from UCB Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WBAG:UCB Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4,632.00 792.00 1,144.00 1,161.00
2018-06-30 4,569.00 872.00 1,105.00 1,083.00
2018-03-31 4,521.50 812.00 1,118.50 1,070.00
2017-12-31 4,474.00 752.00 1,132.00 1,057.00
2017-09-30 4,399.50 708.00 1,138.00 1,046.50
2017-06-30 4,325.00 664.00 1,144.00 1,036.00
2017-03-31 4,236.00 603.50 1,133.00 1,028.00
2016-12-31 4,147.00 543.00 1,122.00 1,020.00
2016-09-30 4,051.00 438.50 1,110.50 1,021.50
2016-06-30 3,955.00 334.00 1,099.00 1,023.00
2016-03-31 3,915.50 299.00 1,097.50 1,030.00
2015-12-31 3,876.00 264.00 1,096.00 1,037.00
2015-09-30 3,773.00 266.00 1,069.00 999.00
2015-06-30 3,670.00 268.00 1,042.00 961.00
2015-03-31 3,507.00 191.50 1,011.00 944.50
2014-12-31 3,344.00 115.00 980.00 928.00
2014-09-30 3,205.50 113.50 963.00 904.50
2014-06-30 3,067.00 112.00 946.00 881.00
2014-03-31 3,100.00 97.00 971.00 883.50
2013-12-31 3,133.00 82.00 996.00 886.00
2013-06-30 3,413.00 153.00 1,061.00 900.00
2013-03-31 3,437.50 192.50 1,068.00 880.50
2012-12-31 3,462.00 232.00 1,075.00 861.00
2012-06-30 3,273.00 161.00 1,066.00 846.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • UCB has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • UCB used its assets more efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
  • UCB has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess UCB's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
UCB has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is UCB's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up UCB's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • UCB is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • UCB's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of UCB's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from UCB Company Filings, last reported 4 months ago.

WBAG:UCB Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6,255.00 1,499.00 1,279.00
2018-06-30 5,942.00 1,668.00 1,028.00
2018-03-31 5,942.00 1,668.00 1,028.00
2017-12-31 5,736.00 1,573.00 1,063.00
2017-09-30 5,736.00 1,573.00 1,063.00
2017-06-30 5,533.00 1,577.00 729.00
2017-03-31 5,533.00 1,577.00 729.00
2016-12-31 5,477.00 1,671.00 761.00
2016-09-30 5,477.00 1,671.00 761.00
2016-06-30 5,067.00 2,161.00 917.00
2016-03-31 5,067.00 2,161.00 917.00
2015-12-31 5,546.00 2,386.00 1,285.00
2015-09-30 5,546.00 2,386.00 1,285.00
2015-06-30 5,128.00 2,333.00 568.00
2015-03-31 5,128.00 2,333.00 568.00
2014-12-31 4,890.00 2,119.00 508.00
2014-09-30 4,890.00 2,119.00 508.00
2014-06-30 4,657.00 2,368.00 677.00
2014-03-31 4,657.00 2,368.00 677.00
2013-12-31 4,323.00 2,750.00 751.00
2013-06-30 4,497.00 2,466.00 415.00
2013-03-31 4,497.00 2,466.00 415.00
2012-12-31 4,593.00 2,102.00 319.00
2012-06-30 4,760.00 2,075.00 315.00
  • UCB's level of debt (24%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (63.5% vs 24% today).
  • Debt is well covered by operating cash flow (72.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 24.2x coverage).
X
Financial health checks
We assess UCB's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. UCB has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is UCB's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.75%
Current annual income from UCB dividends. Estimated to be 1.87% next year.
If you bought €2,000 of UCB shares you are expected to receive €35 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • UCB's pays a higher dividend yield than the bottom 25% of dividend payers in Austria (1.38%).
  • UCB's dividend is below the markets top 25% of dividend payers in Austria (4.44%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WBAG:UCB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 32 Stocks 3.4%
Austria Market Average Dividend Yield Market Cap Weighted Average of 51 Stocks 3.6%
Austria Minimum Threshold Dividend Yield 10th Percentile 1%
Austria Bottom 25% Dividend Yield 25th Percentile 1.4%
Austria Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WBAG:UCB Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 1.46 4.00
2022-12-31 1.39 4.00
2021-12-31 1.35 10.00
2020-12-31 1.27 14.00
2019-12-31 1.18 13.00
WBAG:UCB Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-02-28 1.210 1.650
2018-02-22 1.180 1.648
2017-02-23 1.150 1.791
2016-02-26 1.100 1.652
2015-03-02 1.060 1.486
2015-02-27 1.060 1.551
2014-04-24 1.040 1.606
2013-04-25 1.020 2.124
2012-03-02 1.000 2.446
2011-03-24 0.980 3.161
2011-03-02 0.980 3.676
2010-04-29 0.960 3.716
2010-01-15 0.720 2.237

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, UCB has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but UCB only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of UCB's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4.2x coverage).
X
Income/ dividend checks
We assess UCB's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can UCB afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. UCB has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of UCB's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Christophe Tellier
COMPENSATION €76,000
AGE 59
TENURE AS CEO 4.3 years
CEO Bio

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively. Mr. Tellier served as an Executive Vice President at Bio Pharma Brands and Solutions at UCB SA until December 31, 2014. Since joining UCB in 2011, he has played a key role in UCB's successes and has been instrumental in helping establish current strategy. He has over 25 years in the pharmaceutical sector, with Ipsen and Novartis where he held several executive positions. He serves as Member of the Board of BIO, Member of the Board of PhRMA, and Member of the Board of WELBIO. He serves as a Vice-President and President Elect of the EFPIA. He serves as Deputy Chair of the IMI Governing Board and Chairman of the Innovation Board Sponsored.

CEO Compensation
  • Jean-Christophe's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Insufficient data for Jean-Christophe to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team Tenure

Average tenure and age of the UCB management team in years:

4.2
Average Tenure
57
Average Age
  • The tenure for the UCB management team is about average.
Management Team

Jean-Christophe Tellier

TITLE
CEO & Executive Director
COMPENSATION
€76K
AGE
59
TENURE
4.3 yrs

Detlef Thielgen

TITLE
CFO & Executive VP
AGE
58
TENURE
11.5 yrs

Charl Van Zyl

TITLE
COO & Executive Vice President
AGE
51
TENURE
2.2 yrs

Dhaval Patel

TITLE
Executive VP & Chief Scientific Officer
AGE
57
TENURE
1.6 yrs

Bharat Tewarie

TITLE
Chief Marketing Officer & Executive VP
AGE
57
TENURE
4.2 yrs

Iris Löw-Friedrich

TITLE
Chief Medical Officer
AGE
58
TENURE
11.2 yrs

Emmanuel Caeymaex

TITLE
Executive VP & Head of Immunology Patient Value Unit
AGE
49
TENURE
4.3 yrs

Jeff Wren

TITLE
Executive VP & Head of Neurology Patient Value Unit
AGE
55
TENURE
4.3 yrs

Pascale Richetta

TITLE
Head of Bone Disorders Patient Value Unit & Executive VP
AGE
59
TENURE
3.3 yrs

Jean-Luc Fleurial

TITLE
Executive VP & Chief Talent Officer
AGE
53
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the UCB board of directors in years:

5.1
Average Tenure
68
Average Age
  • The tenure for the UCB board of directors is about average.
Board of Directors

Evelyn de Bergendal

TITLE
Chairman
COMPENSATION
€230K
AGE
68
TENURE
2 yrs

Jean-Christophe Tellier

TITLE
CEO & Executive Director
COMPENSATION
€76K
AGE
59
TENURE
5.1 yrs

Pierre Gurdjian

TITLE
Vice Chairman
COMPENSATION
€129K
AGE
57
TENURE
2 yrs

Mark Eyskens

TITLE
Honorary Chairman
COMPENSATION
€16K
TENURE
14.3 yrs

Georges Hagen

TITLE
Honorary Chairman
COMPENSATION
€30K
AGE
78

Karel Boone

TITLE
Honorary Chairman
COMPENSATION
€49K
AGE
75

Gerhard Mayr

TITLE
Honorary Chairman
COMPENSATION
€70K
AGE
72

Daniel Janssen

TITLE
Honorary Deputy Chairman
COMPENSATION
€29K
AGE
82

Bert De Graeve

TITLE
Independent Director
COMPENSATION
€106K
AGE
63
TENURE
9.1 yrs

Kay Davies

TITLE
Independent Director
COMPENSATION
€121K
AGE
67
TENURE
5.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess UCB's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. UCB has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company’s core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company’s product pipeline includes Evenity for the treatment of osteoporosis; midazolam nasal spray to treat acute repetitive seizures; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 and UCB0159 for immunology; and UCB0599 and UCB0107 for neurology. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Details
Name: UCB SA
UCB
Exchange: WBAG
Founded: 1928
€13,027,128,367
188,908,474
Website: http://www.ucb.com
Address: UCB SA
Allée de la Recherche, 60,
Brussels,
Brussels, 1070,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR UCB Common Shares Euronext Brussels BE EUR 02. Jan 1980
OTCPK UCBJ.F Common Shares Pink Sheets LLC US USD 02. Jan 1980
DB UNC Common Shares Deutsche Boerse AG DE EUR 02. Jan 1980
LSE 0NZT Common Shares London Stock Exchange GB EUR 02. Jan 1980
WBAG UCB Common Shares Wiener Boerse AG AT EUR 02. Jan 1980
BATS-CHIXE UCBB Common Shares BATS 'Chi-X Europe' GB EUR 02. Jan 1980
OTCPK UCBJ.Y UNSPONSORED ADR Pink Sheets LLC US USD 10. Feb 2009
Number of employees
Current staff
Staff numbers
6,828
UCB employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 22:11
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/20
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.